HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petersen, P. Search for Related Content PubMed PubMed Citation Articles by Petersen, P.

Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation

SPORTIF ii: a dose-guiding, tolerability, and safety study

Palle Petersen, MD, DMSc, FCCP^*,*, Margaretha Grind, MD, PhD, John Adler, MSc SPORTIF II Investigators

^* Department of Neurology, University State Hospital, Rigshospitalet, Copenhagen, Denmark
Department of Clinical Science and Medicine, AstraZeneca R&D Charnwood, Loughborough, United Kingdom
Department of Biostatistics, AstraZeneca R&D, Mölndal, Sweden

View larger version (13K): [in a new window]   Figure 1 Design and treatment dosages of the SPORTIF II study. bid = twice daily; INR = International Normalized Ratio.

View larger version (14K): [in a new window]   Figure 2 Proportion of patients taking warfarin within defined International Normalized Ratio (INR) ranges, as determined at a central laboratory.

View larger version (16K): [in a new window]   Figure 3 Cumulative number of patients by treatment group who developed minor, multiple minor, and major bleeding during the study.